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doi:10.1016/j.jtcvs.2006.09.053bjective: Aberrant activation of the Wnt signaling pathway is associated with the
athogenesis of multiple cancers, including non–small cell lung cancer. Wnt inhib-
tory factor, a secreted Wnt antagonist, is downregulated in non–small cell lung
ancer. We hypothesized that restoration of Wnt inhibitory factor function would
nhibit lung cancer cell growth.
ethods: The lung cancer cell lines A549 and H460 were transfected with an
xpression vector containing the Wnt inhibitory factor gene. Apoptosis rates and
olony formation were measured after transfection. Recombinant Wnt inhibitory
actor protein was used to treat H460 cells, and proliferation rates were measured
ith an MTS assay. Finally, Wnt inhibitory factor plasmid was peritumorally
njected near H460 tumor xenografts in nude mice.
esults: Wnt inhibitory factor–transfected cells had increased apoptosis and de-
reased colony formation than control cells. Recombinant human Wnt inhibitory
actor protein was also able to inhibit H460 cell proliferation measured by using the
TS assay. Wnt inhibitory factor plasmid significantly inhibited the growth in vivo
f H460 tumor xenografts in nude mice.
onclusion: These data suggest that Wnt inhibitory factor is able to inhibit lung
ancer cell growth both in vitro and in vivo and provides additional evidence that
nt inhibitory factor plays an important role in Wnt pathway regulation in lung
ancer.
s the leading cause of cancer death worldwide, lung cancer poses a major
public health problem. Non–small cell lung cancer (NSCLC) comprises
75% to 80% of lung cancer cases.1 Despite recent advances in treatment,
verall prognosis remains poor, and the overall 5-year survival rate remains at
5%.2 A better understanding of the molecular pathogenesis of lung cancer might
ead to more effective targeted therapies.
The Wnt signaling pathway is a key developmental pathway that has also
een implicated in oncogenesis.3,4 It plays an important role in normal embry-
nic and stem cell development but is dormant in most adult tissues. Aberrant
eactivation of the Wnt pathway has been shown in multiple human cancers,
ncluding NSCLC.5-10
The Wnt pathway is regulated by the complex interplay of multiple agonists and
ntagonists. One such antagonist is Wnt inhibitory factor (WIF-1).
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G
TSWIF-1 is a naturally occurring secreted protein that binds
he Wnt ligand.11 Downregulation of WIF-1 has been shown in
ultiple cancers.12-14 We recently reported that WIF-1 was
ownregulated and silenced by promoter hypermethylation in
SCLC.15
We hypothesized that restoration of WIF-1 function
ould inhibit the Wnt pathway and thus inhibit lung cancer
ell growth.
aterials and Methods
ell Lines
SCLC cell lines (NCI-H460 and A549) were obtained from
merican Type Culture Collections (Manassas, Va). NSCLC cell
ines were cultured in RPMI 1640 supplemented with 10% fetal
ovine serum, penicillin (100 IU/mL), and streptomycin (100
g/mL).
ransfection
he human WIF-1 open reading frame was cloned into a mam-
alian expression vector, pcDNA3.1, obtained from Invitrogen
Carlsbad, Calif). Twenty-four hours before transfection, 2 
05 cells (H460 or A549) were plated in 6-well plates. Eight
icrograms of WIF-1 plasmid was transfected per well by using
ipofectAMINE 2000 (Invitrogen), according to the manufac-
urer’s protocol. Eight micrograms of pcDNA3.1 vector containing
he lac-Z gene (Invitrogen) was transfected into cells as a control.
emiquantative Reverse Transcription–Polymerase
hain Reaction
eventy-two hours after transfection, H460 and A549 cells were
reated with trypsin and harvested. Total RNA from was isolated
ith an RNeasy Mini Kit (Qiagen, Valencia, Calif), according to
he manufacturer’s protocol. Reverse transcription–polymerase
hain reaction (RT-PCR) was performed in a GeneAmp PCR
ystem 9700 (Applied Biosystems, Foster City, Calif) by using an
T-PCR kit (SuperScript One-step RT-PCR with Platinum Taq
it, Invitrogen) for 25 cycles, according to the manufacturer’s
rotocol. Primers for RT-PCR were obtained from Operon Tech-
ologies, Inc (Alameda, Calif). Primer sequences for the human
IF-1 cDNA were 5=-CCGAAATGGAGGCTTTTGTA-3= (for-
ard) and 5=-TGGTTGAGCAGTTTGCTTTG-3= (reverse), prim-
rs for c-MYC were 5=-TTCGGGTAGTGGAAAACCAG-3= (for-
ard) and 5=-CAGCAGCTCGAATTTCTTCC-3= (reverse), and
rimers for cyclin D1 were 5=-CTGTCGCTGGAGCCCGTGAA-3
7 (forward) and 5=-TGGCACAGACCCGAACGAAG-3= (re-
erse). Glyceraldehyde-3-phosphate dehydrogenase was used as
n internal control. RT-PCR products were then electrophoresed
Abbreviations and Acronyms
RT-PCR reverse transcription–polymerase chain
reaction
WIF-1 Wnt inhibitory factorn an agarose gel and photographed under UV light. N
34 The Journal of Thoracic and Cardiovascular Surgery ● Marcpoptosis Assay
hree days after transfection, cells were harvested after treatment
ith trypsin. They were then stained with an Annexin V FITC
poptosis Detection Kit (Invitrogen Biosource, Carlsbad, Calif),
ccording to the manufacturer’s protocol. Then stained cells were
mmediately analyzed by means of flow cytometry (FACScan;
ecton Dickinson, Franklin Lakes, NJ).
olony Formation Assay
ransfection was performed as above. Twenty-four hours after
ransfection, cells were stripped and plated on 6-well cell-culture
ishes. The cells were then selected by using G418 (400 g/mL).
wo weeks after selection, colonies were stained with 0.5% crystal
iolet solution and counted.
ecombinant WIF-1 and Cell Proliferation Assay
urified recombinant human WIF-1 protein was obtained from
&D Systems (Minneapolis, Minn). The protein was resuspended
n phosphate-buffered saline to obtain concentrations of 1 g/L.
H460 cells were plated at 5  103 cells per well in RPMI
edium in a 96-well culture plate. Twenty-four hours after plating,
alf the cells were treated with recombinant WIF-1 protein, and
alf were treated with bovine serum albumin (BSA) (Sigma-
ldrich, St Louis, Mo) to achieve a concentration of 20 g/mL.
edium was changed after 96 hours, at which point WIF-1 or BSA
as again added to achieve concentrations of 20 g/mL. The
ercentage of live cells was evaluated by incubating for 2 hours
ith the Celltitre 96 Aqueous Non-radioactive Cell Proliferation
ssay (Promega, Madison, Wis). Plates were read with a spectro-
hotometer at a wavelength of 490 nm. Measurements were made
t 3 time intervals: 24 hours after treatment, 96 hours after treat-
ent, and 192 hours after treatment. Three wells from each treat-
ent group were measured for each time point.
umor Xenografts
ll in vivo experiments were performed in accordance with the
niversity of California, San Francisco institutional guidelines
institutional review board A8714-25971-01). Groups of 8 female
thymic nude mice (strain NCRNU-M, 5-6 weeks old) received
ubcutaneous injections with 1 107 H460 cells in the dorsal area
t a volume of 100 L. Three days later, the tumors were uni-
ormly formed. We then subcutaneously injected the mice twice
eekly in the peritumoral area with either 50 g of WIF-1 vector
r empty pcDNA3.1 vector in 100 L of lipofectamine. Tumor
ize was determined at weekly intervals for 3 weeks, and tumor
olume was calculated by using width (x) and length (y; [x2y/2,
here x if less than y]). After the mice were killed, tumors were
esected and weighed.
tatistical Analysis
he data shown represent mean values  standard deviation. The
npaired t test was used to compare different treatments and
etermine the P value.
esults
reviously, we found that WIF-1 was underexpressed in the
SCLC cell lines H460 and A549.15 An expression vector
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G
TSontaining the WIF-1 gene was transfected into H460 and
549 cells to test whether WIF-1 can inhibit growth and
nduce apoptosis in these cell lines. Vector containing lac-Z
as used as a control. We confirmed increased WIF-1
xpression in the WIF-1–treated cells by performing semi-
uantitative RT-PCR on RNA extracted from WIF-1– and
ac-Z–transfected cells (Figure 1).
We confirmed downregulation of the Wnt pathway by
easuring expression of the Wnt target genes c-MYC and
yclin D1 by using semiquantitative RT-PCR. We found
hat lung cancer cells transfected with WIF-1 had decreased
xpression of c-myc and cyclin D1 (Figure 2). Transcription
f both signals has been shown to be mediated by -catenin
hrough the TCF binding site.16-18
Three days after transfection, we found significantly
ncreased apoptotic cell death in cells transfected with
IF-1 (P  .05, Figure 3). Having found increased apo-
tosis in WIF-1–transfected cells, we then assessed the
ffect of WIF-1 on growth inhibition. We selected for trans-
ected cells and found that after selection, cells transfected
ith WIF-1 formed dramatically fewer colonies than did
ells transfected with control vector (Figure 4).
We then used recombinant human WIF-1 to validate the
ffect of WIF-1 in NSCLC cells. Purified recombinant hu-
an WIF-1 protein was added to the medium of H460 cells
igure 1. Reverse transcription–polymerase chain reaction for
nt inhibitory factor (WIF-1) in A549 and H460 cells transfected
ith either lac-Z (control) or WIF-1. The fragment of human WIF-1
DNA amplified is 188 bp.
igure 2. Reverse transcription–polymerase chain reaction for
yclin D1 and c-myc in A549 and H460 cells transfected with either
ac-Z (control) or Wnt inhibitory factor (WIF-1). Glyceraldehyde-
-phosphate dehydrogenase was used as a control transcript. 0
The Journal of Thoraciclated in 96-well plates. We used an MTS assay to assess
ell proliferation at 24 hours, 96 hours, and 192 hours after
reatment. We found that recombinant human WIF-1 sig-
ificantly inhibited cell growth after 8 days of incubation
Figure 5).
Finally, we assessed the effect of WIF-1 transfection in
n in vivo tumor xenograft model. Nude mice were subcu-
aneously injected with H460 cells and then treated with
eritumoral injections of WIF-1 plasmid or empty vector.
e found the WIF-1 plasmid significantly inhibited tumor
rowth (Figure 6, A). After 4 weeks of treatment, the tumors
reated with the control weighed more than 3 times as much
s tumors treated with WIF-1 (P  .05; Figure 6, B). There
igure 3. Annexin V analysis of apoptosis. Seventy-two hours
fter transfection with either lac-Z (control) or Wnt inhibitory
actor (WIF-1), A549 and H460 cells were harvested by means of
rypsinization and stained with an Annexin V-fluorescein isothio-
yanate kit. The bar graphs show the percentage of apoptosis,
hich represents the number of Annexin V cells out of the total
umber of cells counted (mean  standard deviation, P < .05).
igure 4. Colony formation assay with A549 and H460 cells. The
ells were transfected with lac-Z or Wnt inhibitory factor (WIF-1)
ector and selected with G418. Colonies were stained by using
.5% methylene blue and counted 2 weeks after the transfection.
and Cardiovascular Surgery ● Volume 133, Number 3 735
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G
TSas no statistically significant difference in the overall
eight of the mice, nor did there appear to be any obvious
oxicity from the WIF-1 treatment.
iscussion
e found that restoration of WIF-1 function caused Wnt
athway downregulation and inhibited NSCLC cell growth.
ransfection with WIF-1 induced apoptosis in NSCLC cells
nd inhibited colony formation. Transfection also inhibited
SCLC tumor xenograft growth. Treatment with recombi-
ant WIF-1 protein also inhibited NSCLC proliferation.
hese results support our previous studies, which showed
hat inhibition of Wnt signaling could inhibit NSCLC cell
rowth.19 The results also reinforce the hypothesis that
ownregulation of WIF-1 is important for Wnt pathway
ctivation in NSCLC.
Aberrant activation of the Wnt pathway has recently
een linked to lung cancer. Traditional alterations in the
nt pathway, such as -catenin and adenomatous polyposis
oli gene mutations are relatively uncommon in lung can-
er.20-22 However, there is growing evidence that other
echanisms of Wnt pathway activation do play an impor-
ant role in lung cancer. We have found evidence of Wnt
athway activation in lung cancer mediated through the
olecule disheveled.7 In addition, multiple studies have
hown downregulation of secreted Wnt inhibitors in lung
ancer.15,23-25 WIF-1 is among these secreted Wnt inhibi-
ors and is known to bind Wnt proteins and inhibit their
ctivities.26 The mechanism of interaction between WIF-1
igure 5. MTS assay of H460 cells treated with recombinant Wnt
nhibitory factor (WIF-1) or BSA for 8 days. A, Proliferation was
easured with the MTS assay at 3 time points: 1 day, 4 days, and
days after treatment. Absorbance was measured at 490 nm 2
ours after addition of MTS reagent. B, MTS assay after 8 days of
reatment. Absorbance at 490 nm is expressed as percentage
roliferation, where control treatment (BSA) is 100% (mean 
tandard deviation, P < .05).nd Wnt remains poorly understood. Unlike the multiple
36 The Journal of Thoracic and Cardiovascular Surgery ● Marcecreted, frizzled related proteins that have been described,
IF-1 lacks any sequence similarity with the cysteine-rich
omain of the Wnt target frizzled receptor.27 Nonetheless,
IF-1 does bind to Wnt proteins in the extracellular space
nd inhibits Wnt-frizzled interactions.11 The relative impor-
ance of WIF-1 among the various Wnt antagonists is also
nclear.
We have previously shown that WIF-1 is downregulated
n the vast majority of NSCLC tumor specimens.15 The
bility of WIF-1 to inhibit NSCLC growth in vitro and in
ivo thus has potential therapeutic implications. These ex-
eriments reinforce the potential of using demethylating
gents to reactivate hypermethylated tumor suppressors in
ancer and raise the possibility of therapy specifically re-
ated to the role of WIF-1 in the Wnt pathway.28
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iscussion
r Y. Joseph Woo (Philadelphia, Pa). Does the WIF block the
anonical and noncanonical Wnts or one group in particular?
Dr Kim. That is a good question. On the basis of our Western
nalysis, it seems that there is some inhibition of the canonical
athway because there is some decrease in -catenin levels. We
ave looked at disheveled levels as a marker of noncanonical
athways, and our results thus far have been mixed. It seems that
n some of the cell lines we have tested, disheveled levels are
ecreased, but in others they stay the same.
Dr Robert J. Cerfolio (Birmingham, Ala). Excellent work.
ongratulations. Now, please take me on your Disney World ride
f the future 3 years, 5 years, 7 years from now. Tell me how you
nvision your data helping us treat patients in the land of tomor-
ow. Is it a targeted therapy with radiotherapy, is it a targeted
herapy with adjuvant chemotherapy, neoadjuvant therapy? How
o you see this affecting patient care 10 years from now?
Dr Kim. That is a great question. I think WIF is a good target
or therapy because it acts in the extracellular space. Therefore a
ot of problems of intracellular delivery can be avoided. However,
hat I did not show you was that the protein concentrations that
e required to actually have an effect were really quite high.
herefore I do not think that recombinant WIF by itself could be
sed as a therapy. We have some other experiments that seem to
ndicate there is some kind of an autocrine effect, as well as a
aracrine effect. I think that future avenues could be something
long the lines of a fusion protein or some type of protein that has
he active moiety along with some other delivery molecule.
Dr Mark J. Krasna (Baltimore, Md). Dr Kim, Dr Byrne and
are curious. What does Wnt stand for, or after whom is it named?
Dr Kim. As I alluded to, the Wnt pathway is a key pathway in
evelopment, and it is named after a combination of the wingless
ene of Drosophila because mutations lead to wing malformation
nd the Int gene in mice, the integration site for the mouse
ammary tumor virus.
and Cardiovascular Surgery ● Volume 133, Number 3 737
